Michael Molony
About Michael Molony
Michael Molony serves as the Executive Director of Analytical Development and Quality Control at Insmed Incorporated, where he has worked since 2024. He has extensive experience in the biotechnology industry, having held various leadership roles at companies such as Avid Bioservices, Allergan, and Sangamo Therapeutics.
Current Role at Insmed
Michael Molony serves as the Executive Director of Analytical Development & Quality Control at Insmed Incorporated. He has held this position since 2024, working on-site in San Diego, California. In this role, he focuses on the design and implementation of strategic plans that align with business objectives, particularly in the fields of gene therapy and gene editing.
Previous Experience in Quality Control
Prior to his current role, Michael Molony held several positions in quality control across various organizations. He was the Director of the Quality Control Department at Avid Bioservices from 2013 to 2015. He also served as the Associate Director of Analytical Development & Quality Control at Gilead Sciences from 2012 to 2013, and as the Director of BioPharm Testing at Allergan from 2007 to 2010.
Leadership in Analytical Development
Michael Molony has extensive experience in analytical development and quality control. He worked as the Vice President of Analytical Development and Quality Control at Sangamo Therapeutics, Inc. from 2020 to 2024. Additionally, he was the Director of Analytical Technologies at Ajinomoto Bio-Pharma Services from 2015 to 2018, and the Director of CMC AD/QC at Ultragenyx Pharmaceutical Inc. from 2018 to 2020.
Educational Background
Michael Molony obtained a Bachelor of Arts (B.A.) in Microbiology with an emphasis in Molecular Biology from UC Santa Barbara, where he studied from 1985 to 1988. He furthered his education by earning a Master of Arts (MA) in Cell/Cellular and Molecular Biology from San Francisco State University, attending from 1994 to 1996.
Expertise in Gene Therapy and CMC Operations
Michael Molony possesses expertise in managing chemistry, manufacturing, and control (CMC) operations, particularly for AAV Gene Therapy-based products. He is skilled in protein chemistry, molecular biology, analytical methods, quality systems, automation, and statistics, which supports his strategic initiatives in the biotechnology sector.